LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
31 hedge funds and large institutions have $3.07M invested in LakeShore Biopharma Warrants in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$159K |
| 2 |
VAM
Valliance Asset Management
Central,
Hong Kong
|
+$114K |
| 3 |
BP
BFAM Partners
Northpoint, Hong Kong,
Hong Kong
|
+$83.3K |
| 4 |
Jane Street
New York
|
+$75.5K |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$74.2K |
Top Sellers
LSBPW Hedge Fund Activity: Q1 2023 in Review
31 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q1 2023, worth a combined $3.07M.
Buyers outnumbered sellers: 31 funds opened new LSBPW positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was LMR Partners, opening a new position worth an estimated $159K.
- 31 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $3.07M of LakeShore Biopharma Warrants stock for Q1 2023.
- 31 funds opened new LakeShore Biopharma Warrants positions in Q1 2023 and 0 closed out, a net change of +31 holders.
- The largest LakeShore Biopharma Warrants buyer in Q1 2023 was LMR Partners, an estimated $159K added.
Based on aggregated 13F filings for Q1 2023.